With the tenth anniversary of the mapping of the human genome recently marked, the question of what science may or may not be able to tell us about our risk for potentially-life threatening diseases is of growing interest, and debate continues about its ethical implications. In the July 24^th issue of JAMA Dr. Robert Klitzman, professor of clinical sociomedical sciences at the Columbia University Mailman School of Public Health and a bioethics expert, shares his concerns in the commentary “Return of Secondary Genomic Findings vs. Patient Autonomy.”